29.08.2011 ARTES and NL join in a strategic collaboration and co-marketing alliance ARTES, specialized in recom-binant protein production and process development from yeast expression systems and the US based company NL Biotech-nologies, owner and specialized in certain tech-nologies for production of vaccines and diagnostic proteins started a strategic collaboration. With signing this collaboration agreement the two companies combine their know-how and technologies in yeast expres-sion, process and vaccine development. The direct and noticeable aim is the marketing of efficient and cost effective vaccines and diagnostics proteins. The first product that is available right from the start is a Hansenula polymorpha derived Hepatitis E vaccine. Proof-of-principle and animal studies (mice and macaques) have been done and shown very good result and high immune answers. “The Hepatitis E transmission is a person-to-person one, normally triggered to the fecal-oral route. Infections occur because of consumption of contaminated water and ingestion of raw or uncooked food – therefore it is a disease most common in developing countries,“ Vitaly Granovskiy, managing director of NL carried out. And Dr. Michael Piontek, managing director of ARTES added, ”With the Hepatitis E process we have another reliable and cost-efficient VLP-based production process in our portfolio. Like for HepB and avian flu, the manufacturing costs for this vaccine are low because of the effective technology behind. In our mind, it should be an inter-esting process particular for developing countries. “ The partners are now looking for companies to out-license the process. 24.06.2011 New Scientific Board Member Prof. PhD David Anderson Burnet Institute, Melbourne, Australia, Deputy Director, Burnet Senior Principal Fellow. Professor Anderson is an expert in Microbiology and Molecular Virology. He has focused his work on understanding the structure and assembly of hepatitis viruses, and the use of this information to design better diagnostics, vaccines and antiviral therapies for control of major viral infections of man. Professor Anderson has published more than 60 original research papers and invited chapters, and has been invited to speak on original research work at numerous national and international scientific meetings. He has been active in translation of research into practical outcomes through commercial ventures and academic collaborations and is an inventor on 10 patent families. We are really proud to welcome Professor Anderson as our new board member and we are pleased that he will support ARTES. We are looking forward to a successful relationship. 03.06.2011 BIO 2011, Washington DC Meet us at the partnering "Business Forum" event of the Bio International Convention 2011 in Washington DC or contact us directly for a personal meeting! The Bio 2011 is taking place from June 27 - 30. Go to BIO website 27.09.2010 ARTES steps further into the vaccine business by acquiring Anavax ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique partner for the vaccine industry. The ANAVAX VLP platform has already been applied to the development of adjuvant-free vaccines against avian and swine flu, malaria and HIV. Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. Together, the platforms build a new approach to low-cost mass production of safe and effective vaccines. ARTES’ business plan is to enhance its position as a preferred development partner for vaccine manufacturer. 29.04.2010 Injectable Sustained Release Formulations of Therapeutic Proteins Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere formulation composed of biocompatible polymers loaded with interferon alpha 2a manufactured from ARTES´ proprietary yeast Hansenula polymorpha expression system. Q-Sphera™ is a highly enabling bio-encapsulation technology for the development of polymer based sustained release systems. No harsh solvents or manufacturing conditions are used in the production of drug (including peptides and proteins) loaded microspheres facilitating benign processing of labile molecules. Hansenula based products, which are already marketed worldwide, are characterized by safety and cost efficiency superior to other microbial technologies. Interferon alpha 2a manufactured from Hansenula has proven to be better tolerated than the E. coli reference. The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with current marketed pegylated therapies through the development of a one month sustained release microsphere formulation. This first phase of the collaboration is expected to be completed by the end of 2010. http://www.q-chip.com 16.11.2009 ARTES and Rhein Minapharm continue their successful product development collaboration Langenfeld and Cairo – ARTES Biotechnology and Rhein Minapharm Biogenetics jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology platform and know-how to the generation of a therapeutic protein chosen by Rhein Minapharm that is typically produced in E coli. Rhein Minapharms´s new target is now produced from the Hansenula platform at considerable higher yields and at reduced costs compared to alternative bacterial or yeast systems. Under the terms of agreement ARTES handed over the production cell lines and received another milestone payment. Additionally, ARTES and Rhein Minapharm extended their collaboration aiming at additional targets for Minapharm´s portfolio. ARTES will be responsible for the generation of new production cell lines and will share the process research and development responsibility with Minapharm. “Our long-term agreement is an important milestone in the existing relationship between our companies and we are really proud that our strain and process development work enables Rhein Minapharm to develop their innovative target pipeline and to save production costs,” said Dr. Michael Piontek, founder and Managing Director of ARTES. Dr. Wafik Bardissi, Chairman and CEO of Minapharm added: “Together with ARTES, we are creating a cross-functional R&D teamwork to further endow our pipeline with affordability and innovation, characteristic of Hansenula derived proteins already in clinical practice and key market drivers of our emerging markets.” http://www.minapharm.com 02.09.2009 ARTES is research partner of ChemBioTec project supported by Deutsche Stiftung Umwelt ARTES Biotechnology today announces the collaboration with 5 other collaboration partners in a joint 28 months research program that is granted by the national Deutsche Stiftung Umwelt within the ChemBioTec initiative. The Deutsche Bundesstiftung Umwelt DBU is one of Europe's largest foundations and promotes innovative and exemplary environmental projects The funded project includes three academic partners and three biotech companies and is coordinated by Prof. Dr. Holger Zorn, Institute of food chemistry and food biotechnology, University Giessen. The interdisciplinary research group has set the aim to study in a first time application the material recycling of straw and wood leftovers by using a fungus secretome. With this project ARTES extends its activities in the area of production of bio-based fine chemicals from renewable resources. 05.08.2009 Exclusive Cooperation between ARTES and the Ukrainian National Academy of Sciences Langenfeld/Lviv, August 5th, 2009 ARTES announced today that it has signed an exclusive Marketing Agreement with the Institute of Cell Biology of the National Academy of Science of Ukraine. Matter of the agreement is that the NAS technology based on the yeast organism Hansenula polymorpha is now exclusively marketed and licensed by ARTES Biotechnology worldwide except for Ukraine. The technology licensed to ARTES covers new expression tools as well as production cell lines for various products, a.o. HepB antigen and Arginase. With this agreement ARTES expands its Hansenula technology platform and gains access to new processes and products. “With the input from NAS”, said Michael Piontek the managing director from ARTES, “we are now once again able to broaden up our expertise in the Hansenula research field. This newest collaboration enables us even more to expand our previous offer and especially with the view of East-European markets we had won an important academic research partner.” 11.05.2009 ARTES enters into a partnership with Henkel in a 3-year research program ARTES Biotechnology GmbH today announces the collaboration with Henkel in a joint three years research program that is granted by the German national BMBF (German Ministery of Education and Research) within the CLIB2021 cluster (Wettbewerb Industrielle Biotechnologie 2021). The cooperation aims at the development and manufacturing of peptides with adhesive properties. ARTES will apply its proprietary technology platforms – the yeast expression technologies Hansenula and Arxula and the Chaperone technology for improved secretion. The generation of production cell lines, analytical assay development, and lab-scale fermentation/down stream process development are ARTES´ responsibilities in this cooperation. Innovative strategies for the production of difficult-to-express adhesive peptides shall be developed, resulting in next generation tools for ARTES´ contract R&D. 28.01.2009 New Scientific Board Member Prof. Dr. em. Hermann Sahm As the former director of the Institute of Biotechnology at the Research Center of Jülich, Prof. Dr. em. Hermann Sahm`s main fields of interest in the last three decades were physiology, enzymology and molecular biology of biotechnical amino acid, vitamin and ethanol production by means of a variaty of different microorganisms. He is an expert in the field of improvement and optimization of production strains by metabolic engineering. We are really proud to welcome Prof. Dr. em. Sahm as our new board member and we would be pleased that he will support ARTES Biotechnology as consultant and network partner. We are looking forward to a successful relationsship. 15.10.2008 New Scientific Board Member Prof. Dr. Holger Zorn, University of technology, Dortmund, leader of the work group technological biochemistry. Prof. Dr. Zorn is an expert in the field of industrial bioengineering and white biotechnology and here in detail for extraction of enzymes from basidiomycete fungi. We are really proud to welcome Prof. Zorn as our new board member and we would be pleased that he will support ARTES Biotechnology as consultant and network partner. We are looking forward to a successful relationship. 27.08.2008 Biotechnica 2008 Also this year ARTES is exhibiting at the Biotechnica in Hannover. You can visit us in hall 9 booth E33, the joint booth of the State of North-Rhine-Westphalia. We look forward to meeting you there. 25.02.2008 ARTES and m2p-labs join forces and offer an exclusive technology combination ARTES Biotechnology GmbH (Langenfeld) and m2p-labs GmbH (Aachen) announced today the start of a long-term collaboration in clone screening and media optimisation. The two companies combine their proprietary technologies and know-how in yeast expression and high throughput fermentation. In this exclusive collaboration the two companies offer strain selection, physiological characterization and media optimization with the two yeast systems Hansenula polymorpha and Arxula adeninivorans. The combination of this high-productive expression systems and the powerful BioLector screening tool provide much more physiological data at a high throughput level in screening and early bioprocess development. Both companies are convinced that their clients will profit from this new technology offer by reduced time lines in strain and process development, the availability of new carbon sources and more productive clones and culture conditions. 14.01.2008 ARTES and Minapharm sign long-term strategic development agreement Langenfeld and Cairo, January 14, 2008 / b3c newswire / ARTES Biotechnology, which is specialized in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed. For further information please choose the link below: http://www.b3c.de/php/popup.php?id=98 30.11.2007 New Technology Launch ARTES is proud to announce the launch of new expression technologies - Arxula and the Wide Range Expression Vector System. Information about these technologies and the offer can be found on the newly designed webpages. 08.10.2007 Exclusive Cooperation between ARTES and IPK ARTES Biotechnology GmbH expands technology platform Obviously the new offices and laboratories in Langenfeld (near Dusseldorf) inspire ARTES´ business and scientific development. Achieving notable success with the Hansenula technology for years, the biotech company has now concluded an exclusive cooperation with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) in Gatersleben. „The aim is a joint research and marketing of a new yeast expression technology“, explains Dr. Melanie Dröttboom, in charge of Business Development at ARTES Biotechnology GmbH. „With the new collaboration we are able to expand our offer and we win an important academic research partner “, says Dröttboom. Prof. Dr. Gotthard Kunze, head of the department of Molecular Cell Biology, stands for the new agreement on behalf of the IPK Gatersleben. „This cooperation helps us to broaden and strengthen the research on the yeast Arxula adeninivorans “, states Prof. Dr. Kunze. ARTES Biotechnology concentrates on applied research and on marketing. 02.10.2007 Biotechnica 2007 ARTES is exhibiting at the Biotechnica 2007 in Hannover. You can visit us in hall 9 booth 16 from October 9 to 11. We look forward meeting you in Hannover! Biotechnica homepage 27.08.2007 ARTES at NEW LOCATION On August 27, 2007, ARTES has moved its laboratories and offices to Langenfeld, near Düsseldorf. The new location provides with 850 sqm more than twice the space as before. With this step ARTES is now optimally equipped for the increasing number of contract R&D projects and own long-term research. NEW CONTACT DETAILS: Elisabeth-Selbert-Str. 9 40764 Langenfeld P: +49 (0)2173 27587-0 F: +49 (0)2173 27587-77 17.07.2007 Important Step for Artes Growing international reputation „We are looking forward to work in an international team“, says Dr. Melanie Dröttboom, in charge of Business Development of the Artes Biotechnology GmbH. The Biotech company in Erkrath (near Düsseldorf) has been confirmed the „development of an aptamer-based microarray for the detection of multiple cancer-biomarkers in serum”. This project will be granted with an amount of round about four million Euro. Apart from Artes Biotechnology GmbH there are six other companies from Spain, Germany, Israel and France involved in this transnational program „Eurotransbio“, supported by the German national BMBF (German Ministry of Education and Research). „This three year cooperation with our international partners enables us to enhance our skills and gives us the chance to enter new markets with a diagnostic product“, states Dr. Dröttboom. 18.12.2006 New European Patent Granted ARTES today announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in significant increase of protein secretion, independent of the nature of product or the size of fermentation. This technology further boosts the already high level of protein secretion in Hansenula, but also in other yeast species. The Calnexin patent is co-owned by ARTES Biotechnology GmbH and Rhein Biotech GmbH. 19.06.2006 PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic alliance for marketing of Elafin Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc./USA (OTCBB: PTEO; WKN: 925981) has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG/PROTEO Inc., in India, Egypt and Argentina. In 2004 PROTEO acquired the exclusive license from ARTES to produce recombinant Elafin using the yeast strain Hansenula polymorpha. PROTEO`s CEO Birge Bargmann stated: “Because of the extensive foreign contacts of ARTES, we expect a breakthrough in the application of Elafin, especially in view of faster regulatory approval procedures.” Both partners regard the intensification of their collaboration as a strategic alliance in which ARTES will initiate and supervise Elafin projects in the intended foreign markets. PROTEO is the first company in Germany, which after having received approval from the German Federal Institute for Drugs and Medical Products (BfArM), has successfully conducted a Phase I clinical trial on humans using a compound manufactured with ARTES` Hansenula-technology. Proteo Biotech AG 14.06.2006 ARTES Biotechnology GmbH and ProteoNic BV start research collaboration Today ARTES Biotechnology GmbH, Germany, and ProteoNic B.V., The Netherlands, announce the start of their research collaboration. Both companies will join forces to investigate on the application of ProteoNic´s proprietary technology for enhancement of gene expression in the methylotrophic yeast Hansenula polymorpha, offered by ARTES. 23.04.2006 Forthcoming events ARTES will present the technology and service offer plus latest achievements and developments at: BIOFINE, Barcelona, on May 4th 2006 and ACHEMA, Frankfurt, on May 17th 2006. To arrange for direct meetings please contact: info@artes-biotechnology.com 02.01.2006 NEW ADRESS Effective January 1st, 2006, ARTES has shifted its operations to a new location in: 40699 Erkrath, Germany Max-Planck-Str. 15a. The new, appr. 400 square meter facility combines now offices and laboratories at one site, increasing ARTES´ capacities and further improving our services. 14.10.2005 Bio-fuel production under ARTES´ license ARTES Biotechnology GmbH, Germany and IOGEN Corporation, Canada have concluded a license agreement regarding the use of yeast to ferment xylose to ethanol. Under this license, ARTES grants the rights to its xylose reductase/xylitol dehydrogenase patent family for the commercial production of bio-ethanol from renewable resources. Dr. Jeffrey Tolan, IOGEN Corporation: "Iogen is the leader in ethanol production from cellulosic biomass. We have been producing fuel ethanol from wheat straw in our demonstration plant in Ottawa, Canada for the past 18 months. The agreement with Artes is an important part of the unique yeast technology that we are using in our plant.” Dr. Michael Piontek, ARTES Biotechnology GmbH: "The agreement with IOGEN is a strong proof for the impact of ARTES` technologies in the area of White Biotechnology, especially on the use of renewable resources. In addition to feed/food enzymes produced and marketed from the Hansenula technology, our xylose fermenting yeast technology is now applied in bio-fuel production." IOGEN Homepage 31.08.2005 ARTES and NOVOZYMES announce collaboration ARTES Biotechnology GmbH, Germany and Novozymes A/S, Denmark today announce the start of a mid-term collaboration on the development of recombinant yeast strains. Under this agreement, ARTES will evaluate its Hansenula expression system for the production of different Novozymes´ target proteins. 15.08.2005 Visit us at Biotechnica, Hannover 18-20 October 2005 booth #D24 Biotechnica 2005 16.06.2005 New patent family Artes Biotechnology GmbH today announces the complete acquisition of the international patent family on a Universal Blood Test Tube – UBT. This hirudinized blood withdrawal tube is the world-wide first approach for the determination of almost all measurement parameters in blood analysis in a single test tube. This tube allows automated and simultaneous analysis of haematological and clinico-chemical parameters in whole blood samples. The recombinant Hirudin used for the coating of the UBT is supplied by ARTES and derived from the patent protected expression system Hansenula polymorpha. The UBT is the first application of a Hansenula derived protein in a medical device. Complete UBT info 10.05.2005 Artes and IMEnz announce collaboration on microbial expression systems Düsseldorf/Groningen: A unique set of microbial hosts for gene expression has become available by the collaboration agreement between the biotech companies Artes Biotechnology (Düsseldorf, Germany) and IMEnz Bioengineering Groningen, The Netherlands). To expand the range of different microbial expression systems Artes and IMEnz agreed on a service, research and development collaboration. Artes will combine its “System Screening Service” with IMEnz` “Genome Exploration Toolbox (GET)” to offer a well-balanced selection of eukaryotic, gram-positive and gram-negative bacteria as hosts for the production of a variety of different proteins. The joint service allows a highly efficient simultaneous screening in the most relevant microbial expression systems to find the host ideally suited expressing client’s gene of interest. GET technology IMEnz Bioengineering 04.03.2005 Artes and AC Biotec join forces in small scale cultivation and expression technology Today Artes Biotechnology GmbH and AC Biotec GmbH announce a collaboration agreement in the area of small scale cultivation and expression technologies using the companies´ proprietary technologies and genuine competencies. Within the collaboration AC Biotec will provide its core competency in the miniaturization of microbial cultivation. ARTES adds the long-term experience in contract R&D in the field of recombinant gene expression, specifically in the proven yeast system Hansenula polymorpha. Artes Biotechnology GmbH, a profitable German biotech company, is offering R&D services for recombinant strain development in microbial expression systems. Artes` customers include multinational players such as DSM Nutritional Products (previously Roche), Danisco and Fuji as well as small and middle sized companies. AC Biotec GmbH is a service provider in the field of bioprocess development, contract manufacturing and technology consulting. The core competence of AC Biotec includes the application of small-scale culture systems and the scaling of bioprocesses in between these systems and technical-scale stirred bioreactors. AC Biotec 31.01.2005 FUJI and ARTES Biotechnology announce collaboration Düsseldorf/Tilburg, 31st. January 2005; Today FUJI Photo Film B.V. and ARTES Biotechnology GmbH announce a collaboration for the development of Hansenula based production strains for a special biopolymer. Launched products derived from the superior yeast Hansenula polymorpha include food ingredients such as Hexose Oxidase as well as Hepatitis B vaccines, Insulin and Interferon alpha. In the project with FUJI ARTES contributes its long experience in production strain generation and fermentation. Dr. Michael Piontek: “For ARTES it is the first step into a completely new market segment and therefore the cooperation opens novel possibilities.” Dr. Henk van Urk: “FUJI Photo Film B.V. is determined to commercialise recombinant gelatins for pharmaceutical applications. As a host system we make use of both Pichia pastoris and Hansenula polymorpha. In order to be able to exploit both systems to the maximum, collaborations are needed with renowned experts in the field of yeast expression systems. Already partnership was established with Rijks Universiteit Groningen (RUG) and now we are glad to announce that we could agree upon a collaboration with ARTES Biotechnology.” 01.12.2004 Proteo Biotech AG signs exclusive License- and Collaboration agreement with Artes Proteo Biotech is producing its Elafin with the patent protected yeast strain Hansenula polymorpha on a recombinant basis for a world market. Proteo has signed an exclusive License- and Collaboration agreement with Artes Biotechnology. „This agreement will enable us to produce Elafin, in a large scale, very economically by using the in-licensed yeast Hansenula polymorpha as an high performance expression system. The License- and Collaboration Agreement is an important milestone on our way to world markets and a sustainable development of the company“, so Walter J. Thomsen, CEO of Proteo. „The commercial use of the Hansenula Technology by Proteo is an additional confirmation for the safety and efficiency of our expression system“, so Dr. Michael Piontek, CEO of Artes Biotechnology. For more information on Elafin please visit http://www.proteo.de 18.10.2004 New Scientific Board Member We are proud to welcome our new Scientific Board Member: Prof. Andrei A. Sibirny, Director of Institute of Cell Biology, NAS of Ukraine. Prof. Sibirny - one of the leading scientists in Hansenula research - will support Artes Biotechnology as consultant and network partner. 07.09.2004 Hansenula polymorpha Worldwide Network 2004 Meet Artes at the third Hansenula polymorpha Worldwide Network, 26th - 29th September 2004, Sardinia, Italy. Presentation by Dr. Adelheid Degelmann, Senior Scientist: Secreted expression of bacterial alginate epimerase in H. polymorpha. For further information please contact us! 08.07.2004 Artes at the Annual SIM Meeting 2004 Artes is glad to host a special session on Hansenula & Pichia: Methylotrophic yeasts for therapeutic proteins and industrial enzymes July 25-29, 2004 Anaheim Marriott, CA For further information please contact us or visit Society of Industrial Microbiology 01.07.2004 Artes announces implementation of Scientific Board To continuously strengthen our technology and know-how in recombinant microbial protein production, we have established a Scientific Board of renowned scientists. We are proud to welcome our founder members: - Prof. Cornelis P. Hollenberg; Head of Institute of Microbiology, Heinrich-Heine-University Düsseldorf, Founder of Rhein Biotech GmbH - Prof. Gotthard Kunze; Institut für Pflanzengenetik und Kulturpflanzenforschung Gatersleben - Dr. Kantcho Lyubenov Lahtchev; Institute of Microbiology, Department of Genetics, Bulgarian Academy of Sciences